Signal active
Bio
Geoffrey von Maltzahn is Co-Founder, Chief Executive Officer, and Director of Tessera Therapeutics, as well as a General Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in medicine and environmental sustainability. He is also a co-founder of Sana Biotechnology, Indigo Agriculture, Kaleido Biosciences (NASDAQ:KLDO), Seres Therapeutics (NASDAQ:MCRB), Axcella Health (NASDAQ:AXLA), Generate Biomedicines, and others.
Geoffrey currently serves as Chief Executive Officer and Director of Generate Biomedicines, Chief Innovation Officer and Director of Indigo, and Director of Kaleido Biosciences and Sana Biotechnology. He recently served as Chief Executive Officer of Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology, and as Kaleido’s Chief Executive Officer, where he led the company from inception to launching multiple clinical studies. Geoffrey also served as Chief Executive Officer of Indigo, where he led the development of the company’s technology platform and the discovery of the company’s first commercial products. Previously, Geoffrey was the Chief Technology Officer of Seres Therapeutics, where he led the discovery of SER-109 and built out the company’s discovery platform.
Geoffrey has been recognized with numerous patent grants, awards, and publications. He is listed as an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed articles. Geoffrey has received a number of awards and honors, including Bloomberg 50's Ones to Watch; Business Insider’s 30 Biotech Leaders Under 40; Endpoints 20 Biopharma Leaders Under 40; Boston Chamber of Commerce Ten Outstanding Young Leaders; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative students at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; and the Harvard-MIT Martha Gray Prize. Geoffrey and his inventions have been profiled by Forbes, The Economist, CNN, Scientific American, Bloomberg Businessweek, Popular Science, MIT Technology Review, and other media.
Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.
Location
Cambridge, Massachusetts, United States, North America
Social
Primary Organization
2000
274
96
66
5001-10000
Venture Capital, Finance, Biotechnology, Business Development, Health Care
Jobs history
3
Sana Biotechnology
Co-Founder and Board Member
2018 - Current
Tessera Therapeutics
Co-Founder, Chief Executive Officer & Board member
2018 - Current
Generate Biomedicines
Co-Founder,CEO and Board member
2017 - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Geoffrey von Maltzahn is the General Partner at Flagship Pioneering, based in United States, North America. With a background in Venture Capital, Geoffrey von Maltzahn has a rich history of leadership and innovation. Geoffrey von Maltzahn studied Ph.D Biomedical Engineering, Medical Physics @ Massachusetts Institute of Technology. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
4
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Nov 01, 2018 | - | Series E - Axcella | Flagship Pioneering | 59.0M |
Nov 18, 2021 | Generate Biomedicines | Series B - Generate Biomedicines | Flagship Pioneering | 370.0M |
Sep 15, 2023 | Generate Biomedicines | Series C - Generate Biomedicines | Flagship Pioneering | 273.0M |
Nov 21, 2023 | Quotient Therapeutics | Seed Round - Quotient Therapeutics | Flagship Pioneering | 50.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.